185 results about "Oncogene" patented technology

The invention relates to an oncogene prediction method based on graph variation self-coding, and belongs to the field of bioinformatics. The method is based on a dual-path neural network framework: a main path processes an original network and features enhanced by a variational auto-encoder (VAE) by using a graph attention network (GAT) so as to capture a complex relationship between nodes; the auxiliary path generates an auxiliary network and features containing global information through an APPNP algorithm, and the auxiliary network and features are aggregated through GraphSAGE to retain structural information. The model introduces jump connection and residual connection to relieve gradient disappearance and enhance feature complementarity. And finally, integrating dual-path information output prediction through a linear layer. The method is verified on a plurality of biological network data sets, the prediction accuracy, robustness and hidden relation recognition capability are remarkably improved, and a reliable tool is provided for cancer research.

The invention discloses an ecDNA (ectodeoxyribonucleic acid) identification method based on scATAC-seq (scATAC-Seq) data. The ecDNA recognition method provided by the invention can be used for accurately detecting copy number amplification, breakpoint quantity and ecDNA feature quantity on the whole cell level. According to the method provided by the invention, the specific carried annular oncogene in the tumor can be identified, the distribution characteristics of the annular oncogene in the genome can be analyzed, and the overall composition of all annular DNAs in a single cell and the specific composition of the single annular DNA can be disclosed. In addition, according to the method, the existence of the circular DNA can be verified through a dyeing experiment, and the reliability of a detection result is ensured.

The invention discloses a method, a system and equipment for detecting internal tandem repeat and a storage medium, and the key points of the technical scheme are as follows: obtaining a first reference sequence according to at least one target exon sequence corresponding to a protooncogene, and obtaining a second reference sequence according to at least one target intron sequence corresponding to the protooncogene; comparing the sequencing data of the to-be-detected sample to the second reference sequence to obtain a first comparison result, extracting an uncompared sequence from the sequencing data according to the first comparison result, and comparing the uncompared sequence to the first reference sequence to obtain a second comparison result; and determining a first detection result according to the second comparison result and a first reference sequence, and performing false positive filtering on the first detection result to obtain a second detection result. According to the invention, false positive can be reduced so as to ensure the accuracy and reliability of subsequent analysis.

The invention relates to a hepatocellular carcinoma gene knockout target library based on multiple omics and a screening method of the hepatocellular carcinoma gene knockout target library, and the gene knockout target library for precise treatment of hepatocellular carcinoma is finally obtained through data collection and integration, data screening and target verification in sequence. According to the invention, through multi-omics data integration and bioinformatics analysis, key driving genes of hepatocellular carcinoma are systematically screened, and the important effects of the genes in occurrence, development, metastasis, drug resistance and immune escape of hepatocellular carcinoma are disclosed; the genes not only deepen the understanding of the hepatocellular carcinoma molecular mechanism, but also provide important theoretical basis and potential intervention targets for the development of targeted therapy and personalized therapy strategies.

The invention provides an SNP (Single Nucleotide Polymorphism) site related to turbot non-ocular side blackening, a primer pair and application, and belongs to the technical field of molecular markers. Wherein an SNP (Single Nucleotide Polymorphism) site related to turbot blackening is positioned at the 277th site of a coding region of the gene notumpectinacetylesterase 2, the basic group of the SNP site is mutated into C from T, and the amino acid is mutated into histidine from tyrosine; one SNP site related to turbot blackening is located at the 1154th site of a coding region of a gene KIT progene-oncogene, and the other SNP site related to turbot blackening is located at the 1154th site of a coding region of a gene KIT progene-oncogene receptor kinase b, the basic group of the SNP site is mutated from A to G, and the amino acid of the SNP site is mutated from aspartic acid to glycine. Researches show that genotype distribution of the SNP site between normal turbots and blackened turbots has significant difference.

The invention relates to the technical field of gene and immune molecule detection, in particular to a method for predicting lung cancer EGFR genotype and immune molecule expression level, and the method specifically comprises the following steps: S1, obtaining a CT image: obtaining the CT image of a non-small cell lung cancer patient, the CT image comprising a tumor area and a peritumor area; s2, image omics characteristics are extracted, wherein the image omics characteristics are extracted from the tumor area and the peritumor area respectively; s3, extracting deep network features: extracting the deep network features from the CT image by using a deep neural network based on an attention mechanism; and S4, constructing a prediction model: inputting the radiomics characteristics and the deep network characteristics into the prediction model, and outputting prediction results of EGFR genotypes and immune molecule expression levels. The method for predicting the lung cancer EGFR genotype and immune molecule expression level has the advantages of non-invasiveness, high efficiency, accurate prediction, clinical practicability, model interpretability and technical compatibility and flexibility.

The invention belongs to the technical field of biological medicine and molecular biology, and provides application of GJB6 in preparation of an esophageal squamous cell carcinoma prognosis evaluation reagent and screening of drugs for targeted treatment of esophageal squamous cell carcinoma. The low expression of the GJB6 is applied to preparation of an esophageal squamous cell carcinoma prognosis evaluation reagent. GJB6 is low in expression in ESCC patients, and ESCC prognosis is poor. And the prognosis of patients with high expression of GJB6 is better. Overexpression of GJB6 inhibits ESCC cell proliferation, migration and invasion and in-vivo tumor enlargement. The GJB6 plays a role of a cancer suppressor gene in ESCC and inhibits cell proliferation, migration and invasion. The AKT signal channel is one of downstream channels for GJB6 to regulate the occurrence and development of ESCC. The AKT inhibitor effectively inhibits GJB6 low-expression ESCC malignant phenotypes, including enhancement of cell proliferation and migration invasion ability and in-vivo tumor enlargement. The AKT is a key therapeutic target of the GJB6 low expression type ESCC.

The invention discloses an oncolytic virus and application of the oncolytic virus in preparation of tumor inhibition drugs. The oncolytic virus is a lentiviral vector, and the lentiviral vector comprises polynucleotide encoding p16 protein or a bioactive part of the p16 protein containing CDKN2A gene, and can effectively inhibit growth of cancer related to CDKN2A gene mutation, so that the problem that the existing oncolytic virus has biological safety risk in delivery of cancer suppressor genes is effectively solved.

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS. HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).

The utility model discloses a portable sampling device for endometrial cancer gene methylation detection in the technical field of sampling devices, which comprises an extraction cylinder, one end of the extraction cylinder is fixedly inserted with a connecting pipe, the inner wall of the connecting pipe is movably inserted with a detachable extraction pipe, and the inner wall of the detachable extraction pipe is movably inserted with a connecting pipe. A plurality of guide blocks are fixedly arranged on the outer wall of the end, inserted into the connecting pipe, of the detachable extraction pipe, the guide blocks are in sliding fit with the inner wall of the connecting pipe, and two toothed plate sealing pieces used for blocking the connecting pipe are movably arranged on the inner wall of the extraction cylinder; after the device is used, the grab handle is firstly detached, then the detachable extraction pipe is detached, and at the moment, the guide block slides along the inner wall of the connecting pipe, so that the connecting pipe drives the transmission gear to rotate reversely, and the two toothed plate sealing pieces are reset along with the reverse rotation of the transmission gear to seal the connecting pipe; therefore, the possibility that external sundries enter the extraction barrel through the connecting pipe when the device is not used is reduced.

Mutations in oncogenes and tumor suppressor factors contribute to the development and progression of cancer. This disclosure describes compounds and methods for restoring DNA-binding affinity of p53 mutants, as well as their use in diagnostic assays to guide the treatment of subjects with said compounds for cancer. The compounds of this disclosure can bind to mutant p53 and restore the ability of p53 mutants to bind to DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers containing p53 mutations.

Provided is reproducible means that enables production of nucleus pulposus progenitor cells (preferably, an active nucleus pulposus progenitor cell phenotype) from desired cells such as terminally differentiated cells and stem cells having pluripotency or multipotency. A nucleus pulposus progenitor cell inducer according to the present invention comprising an effective amount of a gene of Brachyury (T) or a homolog thereof, at least one selected from the group consisting of SRY-box6 (SOX6) or a homolog thereof and Forkhead Box Q1 (FOXQ1) or a homolog thereof, and MYC Proto-Oncogene, BHLH Transcription Factor (cMyc) or a homolog thereof (nucleus pulposus progenitor cell master regulator transcription factor), or a product thereof.

The present disclosure features chemical entities (e.g., compounds or pharmaceutically acceptable salts thereof) that degrade the proto-oncogene VAV1 protein (VAV1). The chemical entities are useful, for example, for treating subjects (e.g., human subjects) with inflammatory or autoimmune disorders.

The present invention discloses a method and system for mining potential proto-oncogenes based on the three-dimensional structure of chromatin, which relates to the field of computational biology technology. The method comprises: obtaining multiple mutation insulation regions based on chromatin data and cancer mutation data, and inputting the regions into a trained binding site predictor to obtain prediction results and destroyed insulation regions; obtaining multiple differentially expressed gene sets based on cancer gene expression data, intersecting the multiple differentially expressed gene sets to obtain a final differentially expressed gene set; intersecting the final differentially expressed gene set and the genes in the destroyed insulation regions to obtain intersection genes; performing survival analysis to obtain analysis results, screening the intersection genes based on the analysis results to obtain genes associated with poor prognosis; and screening the intersection genes to obtain potential proto-oncogenes. This improves the accuracy and reliability of mining potential proto-oncogenes while saving time and economic expenses.

The invention discloses an immortalized rabbit liver cell line as well as a construction method and application thereof, and the construction method is characterized in that an exogenous oTERT gene is introduced into rabbit embryo liver cells, so that the rabbit embryo liver cell line is immortalized. The successfully immortalized rabbit embryo liver cell line can be stably subcultured for more than 10 generations, and does not have an aging phenomenon. Compared with a traditional method (introducing exogenous immortalized genes such as cancer suppressor genes p53 and SV40TAg into cells), the TERT-mediated cells belong to normal cells, the growth characteristics of the TERT-mediated cells are kept consistent with those of the normal cells, the TERT-mediated cells belong to immortalization in a real sense, and a scientific and stable cell material can be provided for subsequent RHDV research. The construction method is simple, easy to implement and easy to popularize.

The present invention includes a method and kit for method for detecting anti-Ro antibody negative Sjögren's syndrome / Sjögren's disease without performing a lip biopsy comprising: obtaining a biological sample from a patient suspected of having an anti-Ro antibody negative Sjögren's syndrome / Sjögren's disease; and detecting if the biological sample has autoantibodies to at least one of: Geminin DNA Replication Inhibitor (GMNN), Kelch Domain Containing 8 A (KLHDC8A), Microtubule Associated Protein RP / EB Family Member 1 (MAPRE1), Nucleoporin 50 (NUP50), or SKI Like Proto-Oncogene (SKIL).

The present disclosure provides antibodies specifically binding N-terminal or C -terminal regions of Cell Adhesion Molecule-Related / Down-Regulated By Oncogenes (CDON) polypeptide, methods of making the same, and methods of treating humans having tumors by administering the antibody.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a cancer suppressor gene SLC26A11 in hyperleukocyte acute B lymphocytic leukemia. The invention discloses an application of a cancer suppressor gene SLC26A11 as a specific molecular marker in preparation of induction treatment reaction, prognosis and risk assessment of high leukocyte acute B lymphocytic leukemia of children, and an application in improvement of sensitivity of chemotherapeutic drugs for high leukocyte acute B lymphocytic leukemia of children. The SLC26A11 is used as a potential target, so that a personalized treatment scheme is provided for HALL patients, the toxic and side effects of chemotherapeutic drugs are reduced, and the treatment effect is improved.

The application discloses an ecDNA recognition method based on scATAC-seq data. The ecDNA recognition method provided by the application can accurately detect copy number amplification, breakpoint quantity and ecDNA feature quantity on the whole cell level. The method provided by the application can recognize specific circular oncogenes carried in tumors, analyze the distribution characteristics of the circular oncogenes in the genome, and reveal the overall composition of all circular DNAs in a single cell and the specific composition of a single circular DNA. In addition, the method can also verify the existence of the circular DNA through a staining experiment, so that the reliability of the detection result is ensured.

A novel compound that is a protein degradation-inducing part of the proto-oncogene tyrosine protein kinase receptor (RET), wherein the RET may be wild-type RET or a mutant form of RET.

Methods and compositions for gene therapy of retinal degeneration related to mutations in MER proto-oncogene, tyrosine kinase (MERTK).

An mRNA vaccine composition is described. The vaccine composition includes an exosome comprising an expression cassette comprising mRNA encoding chimeric / fusion / hybrid oncogene (CFHON). Methods of treating or preventing cancer in a subject by administering a therapeutically effective amount of the mRNA vaccine composition are also described.

The application relates to a circular triplex-forming oligonucleotide, a preparation method and application in preparation of tumor-targeting drugs. The circular triplex-forming oligonucleotide (Cir-TFO) is composed of two oligonucleotide chains A and B, each of which comprises a first complementary sequence, a first connecting sequence, a target sequence, a second connecting sequence and a second complementary sequence from the 5' end to the 3' end. The first complementary sequences of the two oligonucleotide chains A and B are reversely and complementarily connected, and the second complementary sequences are reversely and complementarily connected to form a closed ring structure. The target sequence is a TFO sequence capable of forming a triplex structure with double-stranded DNA in the promoter region of a target gene through Hoogsteen hydrogen bonds, and the target gene is selected from a proto-oncogene, an anti-apoptotic gene or a tumor metabolism-related gene.

The present invention belongs to the field of molecular biology detection, specifically, to the field of lung cancer detection, and more specifically, to the detection of methylation levels of lung cancer gene markers. The present invention provides a methylation marker combination for auxiliary detection of lung cancer, comprising: a region in the AHDC1 gene as shown in SEQ ID NO: 1. The sensitivity, specificity and AUC of lung cancer detection using the markers of the present invention are 88.49%, 91.43% and 0.936, respectively. The present invention can detect lung cancer clinically with fewer markers, saving both cost and time, and can detect patients who are truly at risk of lung cancer malignancy in the early stages of the carcinogenesis process with high sensitivity and high specificity.

This invention is directed to methods of reducing incidence or reducing severity or preventing progression of or preventing or treating or preventing pathogenesis of a cancer in a subject, wherein said subject is predisposed to, showing early indications of or suffering from cancer, or methods of reducing intracellular bacterial infection in subjects at risk for or suffering from carcinoma, or from pre-neoplastic or metaplastic tissue changes, comprising contacting at least one cell in an affected tissue in said subject with an agent reducing intracellular bacterial infection in affected tissue, reducing localization of intracellular bacteria proximally to nuclei in cells of affected tissue, or a combination thereof. This invention is further directed to methods of personalized optimized diagnosis and therapy in a subject, comprising screening a subject predisposed to, or at risk for cancer and identifying whether the pre-cancerous or cancerous tissue in the subject is intracellularly infected with bacteria, optionally assessing the intracellular localization of the bacteria-containing compartment to determine a distance of same from a nucleus in the cell; optionally assessing the oncogene profile expression in the subject, and further scoring the subject in terms of the prognosis and potential for therapy and then treating the subject to reduce the intracellular bacterial burden, promote re-localization of the bacterial compartment to be at a further distance from the nucleus, successfully eradicate intracellular bacterial infection, prevent or reduce cell-to-cell spread of the bacteria or any combination thereof. Compositions and kits for effecting the methods of this invention are also provided. This invention still further provides a system for identifying patients who would benefit from adjunctive antimicrobial therapies, enhancing treatment outcomes by providing comprehensive microbial feature characterization, including spatial localization of key microbes associated with treatment resistance in an integrated platform with advanced machine learning algorithms, ultimately providing a personalized patient assessment, enhancing treatment outcomes and optimizing therapeutic strategies.

Provided are a method and a combination for one-tube simultaneous detection of tumor-specific gene mutation and methylation, and the use thereof. The method comprises searching a database to select mutation and methylation sites of a cancer driver gene and a cancer suppressor gene, synthesizing capture probes correspondingly paired with a target interval, performing hybrid capture on an amplification product of a sample treated with a restriction endonuclease by using a probe set comprising tumor-specific gene mutation and methylation capture probes, constructing a high-throughput sequencing library containing a target region, and performing high-throughput sequencing to obtain the sequence of a target fragment, so as to obtain the results of methylation, point mutations and indel variation of a cancer-associated gene. The provided method enables one-tube simultaneous detection of mutation and methylation states of a cancer-associated gene in one assay, requires a low content of a gene to be detected, can be used for methylation and mutation detection of a tumor-specific DNA, and has low detection costs and high efficiency.

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and / or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS, HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).

The present invention relates to a pharmaceutical composition comprising a Runx3 gene or protein as an active ingredient for prevention or treatment of K-Ras mutant lung cancer. Specifically, Runx3 gene-deleted, K-Ras gene-activated lung cancer mice established in the present invention were found to be completely cured without lung cancer recurrence likelihood when restoring the Runx3 gene, compared to the conventional approach of inhibiting the activated cancer gene. Thus, the composition comprising Runx3 protein, a polynucleotide coding therefor, a vector carrying the polynucleotide, or a virus or cell transformed with the vector as an active ingredient according to the present invention can be advantageously used as a composition for prevention or treatment of K-Ras mutant lung cancer.

The present disclosure relates to proteolysis-inducing compounds against the proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild-type RET or a mutant form of RET, which are useful in the treatment of diseases and disorders mediated by said protein, and have formula (I): TIFF2025540907000060.tif43113

The present invention relates to the field of medical information technology, in particular to a construction method, system and medium of a liver cancer gene database. The method constructs a spatial neighborhood relationship based on cell spatial coordinates, and defines a group of interconnected cells as a spatial neighborhood hyperedge; annotates functional modules according to gene expression values, and associates cell nodes within the same functional module as functional module hyperedges; constructs a spatio-temporal dynamic hypergraph structure based on the spatial neighborhood hyperedges and functional module hyperedges; performs local aggregation on the node features of the spatio-temporal dynamic hypergraph structure to obtain a gene expression correlation weight matrix between a target node and domain nodes, thereby constructing a liver cancer gene database. The present invention comprehensively depicts the spatial interaction network, the dynamic evolution of functional modules and the gene expression correlation of liver cancer cells, providing high-quality data support and an analysis platform for the study of liver cancer mechanisms.